American Gene Technologies International Inc.

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Novartis AG outlined the details of its spin-off plans for its generics and biosimilars business Sandoz on 18 August, revealing the financial terms for the big pharma’s shareholders and the date of t